Orchestra Biomed Holdings Inc
OBIO
View Detailed Chart
4.410USD
+0.060+1.38%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
249.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.38%
5 Days
+2.56%
1 Month
-2.65%
6 Months
+46.51%
Year to Date
+10.25%
1 Year
-10.37%
View Detailed Chart
TradingKey Stock Score of Orchestra Biomed Holdings Inc
Currency: USD Updated: 2025-12-22Key Insights
Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 114/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.33.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Orchestra Biomed Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
13.333
Target Price
+203.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Orchestra Biomed Holdings Inc Highlights
StrengthsRisks
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.64M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.64M.
Overvalued
The company’s latest PE is -2.46, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.17M shares, decreasing 0.76% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 380.51K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.02.
Orchestra Biomed Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Orchestra Biomed Holdings Inc Info
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Ticker SymbolOBIO
CompanyOrchestra Biomed Holdings Inc
CEOHochman (David P)
Website
FAQs
What is the current price of Orchestra Biomed Holdings Inc (OBIO)?
The current price of Orchestra Biomed Holdings Inc (OBIO) is 4.410.
What is the symbol of Orchestra Biomed Holdings Inc?
The ticker symbol of Orchestra Biomed Holdings Inc is OBIO.
What is the 52-week high of Orchestra Biomed Holdings Inc?
The 52-week high of Orchestra Biomed Holdings Inc is 6.300.
What is the 52-week low of Orchestra Biomed Holdings Inc?
The 52-week low of Orchestra Biomed Holdings Inc is 2.200.
What is the market capitalization of Orchestra Biomed Holdings Inc?
The market capitalization of Orchestra Biomed Holdings Inc is 249.01M.
What is the net income of Orchestra Biomed Holdings Inc?
The net income of Orchestra Biomed Holdings Inc is -61.02M.
Is Orchestra Biomed Holdings Inc (OBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Orchestra Biomed Holdings Inc (OBIO) has an overall rating of Buy, with a price target of 13.333.
What is the Earnings Per Share (EPS TTM) of Orchestra Biomed Holdings Inc (OBIO)?
The Earnings Per Share (EPS TTM) of Orchestra Biomed Holdings Inc (OBIO) is -1.795.
Related Instruments
-0.68%
-0.20%
+1.37%
+1.29%
+1.43%
+0.86%
+0.35%
-0.93%
-0.19%
+0.78%
+1.07%
+1.35%
-0.31%
+0.25%
+0.59%
+0.99%
+0.74%
+0.93%
+1.27%
+0.65%
